Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

Researchers at the University of California San Diego are hoping to drastically shorten the time between a cancer diagnosis ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...

It’s hard to believe it was almost 20 years ago when in 2005, Patrick Dempsey originated the role of Dr. Derek Shepherd in a ...

A simple blood test could soon predict which ovarian cancer patients will stop responding to their treatment, paving the way ...

Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate.

In May of last year, Dr Shivani Biswal began experiencing severe abdominal pain, bloating, and fever. Initially, she assumed ...

AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...